Background Regulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on ...
Lai JS, Nowinski C, Victorson D, Bode R, Podrabsky T, McKinney N, Straube D, Holmes GL, McDonald CM, Henricson E, Abresch RT, Moy CS, Cella D. Quality of life measures in children with neurological conditions: pediatric Neuro-QOL. Neurorehabil Neural Repair. 2012;26(1):36–47. ...
Development and validation of a novel web application for patient-reported outcome measures monitoring. e23173#Background:Patient Reported Outcome Measures (PROM) and its role in managing cancer treatment associated symptoms can not only improve the quality o... R Jones,A Santoki,M Peter,... -...
This paper applies a theory-driven approach to explore why the use of patient-reported outcome (PRO) measures in clinical practice, in particular, health-related quality of life (HRQoL) instruments, has little or no apparent influence on clinical decision making. A theory-driven approach involves...
Childhood epilepsy is one of the most important and prevalent neurological conditions in the developing years. Persons with childhood onset epilepsy are at... GM Ronen,DL Streiner,P Rosenbaum - 《Health & Quality of Life Outcomes》 被引量: 144发表: 2003年 Quality of life before intensive care...
Adequate daily activity, specifically walking, has been demonstrated to be strongly linked to life expectancy, morbidity and quality of life (QoL) in other neurological conditions, such as stroke3. Furthermore, walking capacity has been shown to be the only independent predictor of survival when ...
In the end, 75 infants were observed, genotyped for MBL2 gene, and followed up to 24 mo of CA for neurological outcome measures. The approval was obtained by the Ethics Committee of the Bambino Gesù Children's Hospital. The parents signed an informed consent at admission of the newborn ...
The Glasgow Outcome Scale (GOS) is one of the earliest outcome measures developed. It has been used frequently in outcome studies after acute neurologic disorders such as traumatic brain injury (TBI) for which it was originally described, as well as stroke and subarachnoid hemorrhage (SAH).18,...
Finally, we elaborate on patient-reported outcome measures (PROMs) as these patient-based measures are increasingly being used in MS trials. 2.1 The Expanded Disability Status Scale The EDSS intends to capture disability of MS patients based on neurological examination by describing symptoms and signs...
Important limitations for the development of biomarkers include the critical need for quantitative, standardized outcome measures for MS disease activity and progression, and validated definitions of treatment response. Using only clinical evidence of disease activity is clearly insensitive as we know from ...